The user is considering adding 2% ketoconazole to their current treatment of oral minoxidil and finasteride to address scalp itchiness and inflammation. Another user suggests controlling inflammation is important for managing hair loss.
Ketoconazole shampoo may help with early-stage hair loss by stopping hair regression and promoting new hair growth, though its effectiveness as a DHT blocker is debated. Users report varying results, with some experiencing dryness and others seeing improvement when used 2-3 times a week.
The user is considering switching from topical finasteride to RU58841 or KX826 due to side effects like low libido and ED. They are also using oral minoxidil and considering low-dose saw palmetto to maintain their hairline.
User discusses a topical hair solution containing Tretinoin, Dutasteride, and Ketoconazole, and asks if it's safe to combine and leave in hair. Concerns include Ketoconazole being left in hair and Tretinoin's effects with Dutasteride and Ketoconazole.
A user underwent a second hair transplant for increased density and to address hair loss in the crown area, with 3,800 grafts at a cost of 2,200 euros at Estepalace, including additional services. Some commenters discussed the appearance of the hairline and the importance of using DHT blockers like finasteride or dutasteride post-transplant.
Ecklonia cava is suggested as an alternative to finasteride and dutasteride for hair growth, potentially offering benefits without their side effects. It is promoted for anti-aging, mood enhancement, and cognitive support.
The conversation is about finding a clearnet vendor for clascoterone, also known as Winlevi, for hair loss treatment. The user is seeking recommendations via direct message.
Mixing charcoal, Ketoconazole, and caffeinated shampoo is questioned for potential interaction, specifically if charcoal inactivates other ingredients. Charcoal is used for seborrheic dermatitis, while caffeine is thought to improve scalp blood flow.
The conversation is about the anticipation of results for a hair loss treatment study, specifically for GT20029, with expectations for the results to be released in the first quarter of 2024. No specific treatments were discussed.
The user is using 5% topical minoxidil, a 0.5mm dermaroller, and keto shampoo for hair loss treatment, showing positive progress after two months. They plan to continue the regimen for maintenance.
TDM-105795 is a potential hair growth stimulant that works differently from minoxidil and could be used alongside it for enhanced growth. It completed phase 2 trials in 2024, with a medium to high chance of release in 2026, but lacks recent updates or phase 3 trial information.
A user was prescribed ketoconazole shampoo by their dermatologist for early-stage hair loss, but is unsure if this is the right treatment. Most commenters suggest seeking a second opinion or starting finasteride treatment immediately, while a few caution about potential side effects.
A user shared progress pictures after 40 days of using topical finasteride, minoxidil, and KX-826 following a hair transplant. They previously used Polaris NR-11, which contains finasteride and minoxidil, and experienced significant hair regrowth.
The user increased their steroid dosage and noticed hair shedding, so they adjusted their regimen by reducing steroid doses and adding oral dutasteride. They are also experimenting with combining RU-58841 and KX-826/pyrilutamide in minoxidil to address hair loss.
The user has been using finasteride, minoxidil, and a derma stamp for 3 months with significant improvement. They are now adding ketoconazole to their routine.
Improving hair health involves not only using treatments like finasteride, minoxidil, and ketoconazole but also focusing on a healthy lifestyle, including diet, exercise, and stress management. A balanced approach enhances treatment effectiveness and overall well-being.
The user is using a hair loss regimen involving 2ddr applied twice daily, tretinoin weekly, and occasionally micro-needling. They report feeling increased scalp thickness and seeing some hair growth progress.
TDM-105795 showed better efficacy and safety in trials for hair loss, with a higher hair count improvement compared to GT20029 and HMI 115, but it's not as widely discussed. The user is questioning why this is the case.
The conversation is about a user offering free unused Eucapil after switching to finasteride for hair loss treatment. The user did not use Eucapil and is willing to give it away locally or ship it if costs are covered.
PP405 shows promise for hair regrowth by manipulating stem cell characteristics and lactate dehydrogenase, with Phase 2a trials pending. Google Ventures' $15M investment suggests confidence, but results and market availability remain uncertain.
PP405 is a potential hair loss treatment that may work by blocking signals that cause hair cells to stop growing, requiring daily application for effectiveness. It could serve as an alternative to minoxidil and finasteride, but it is not yet available on the market and may take several years to be released.
The user experienced severe scalp issues and hair loss after using ketoconazole shampoo, which worsened despite various treatments. They seek advice on restoring scalp health, suspecting an allergic reaction or imbalance caused by the shampoo.
PP405 is a potential hair loss treatment that inhibits mitochondrial pyruvate carriers, increasing lactate dehydrogenase activity and stimulating hair follicle stem cells. In a phase 1 trial, 31% of participants showed over 20% hair density increase with PP405 treatment.
Emerging hair loss treatments like PP405, a topical MPC inhibitor, show promise in activating stem cells for hair growth. The conversation seeks information on the development stages and accessibility of these treatments.
Koshine is considered less effective than finasteride, dutasteride, and RU58841 for hair loss treatment. One user reported positive results with Koshine, but others found it ineffective.
A user shared their 2-year progress using finasteride every other day with no side effects. Others discussed their experiences, shedding cycles, and patience with the treatment.
The conversation discusses the delay in bringing FAK inhibitors and Stanford's hydrogel to market for hair transplants, with a preference for FAK inhibitors over Verteporfin due to their superior potential in preventing scarring. The user expresses frustration over the slow progress and hopes for faster development by companies like FAKnostics.